Published on 04/12/2025

Reproducibility in CI/CD: Seeds, Libraries, and Images

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into Good Practice (GxP) analytics has significantly transformed the pharmaceutical industry’s approach to data management and validation. Understanding the processes involved in model verification and validation (V&V) is vital, particularly in ensuring compliance with regulatory standards such as those set by the FDA, the European Medicines Agency (EMA), and the Medicines and Healthcare products Regulatory Agency (MHRA). This tutorial guide provides a step-by-step overview of the verification, validation, and governance of AI/ML models within continuous integration/continuous deployment (CI/CD) pipelines.

Step 1: Understanding the Components of CI/CD in AI/ML

CI/CD methodologies focus on the automation of software development processes, which allows for frequent code changes while maintaining the stability and integrity of applications. In the context of AI/ML model development, the following components are essential:

• Seeds: These initiate the generation process within AI models, influencing reproducibility and outputs.
• Libraries: The use of specific ML libraries determines the available algorithms and functionalities, impacting performance and compliance.
• Images: In AI, images can refer to container images in CI/CD that encapsulate the environment for running applications.

Each of these components plays a significant role in ensuring that models are not only functional but also compliant and reproducible. The goal is to maintain consistency, accuracy, and reproducibility in each deployment or version of an AI/ML model.

Step 2: Defining Intended Use & Data Readiness

Successful AI/ML model validation starts with a clear definition of intended use and ensuring data readiness. The intended use encompasses the purpose and applications of the model, which is necessary to assess its compliance with regulatory expectations. Factors to consider include:

• Use Case Definition: Clearly identify what the model is designed to achieve. This can affect risk management and regulatory submissions.
• Data Requirements: Ensure that the data used for training, validation, and testing is suitable, complete, and representative of the intended operational environment.

Data readiness extends to the curation of data, ensuring it meets quality standards for model training. Data should be documented meticulously, referring to the requirements of 21 CFR Part 11 regarding electronic records and signatures, as well as compliance with GxP regulations.

Step 3: Bias and Fairness Testing

Testing for bias and fairness in AI/ML models is integral to their validation process. Models should be evaluated to ensure that they perform equitably across diverse population groups. Key actions include:

• Developing a Bias Testing Framework: This framework should clearly outline how bias will be measured and mitigated.
• Assessing Model Outputs: Analyze model predictions and evaluate them against disparate groups to ensure that there are no unintended biases in model behavior.

The process of bias and fairness testing not only aligns with ethical considerations but also addresses regulatory concerns regarding the safety and efficacy of AI applications in pharmaceuticals.

Step 4: Model Verification and Validation Process

The model verification and validation process is an essential step in the life cycle of an AI/ML model. The purpose of this step is to ensure that models perform according to their intended use. This involves:

• Verification: Ensures that the model is built correctly according to specifications. This includes reviewing the implementation, code reviews, and performance benchmarks.
• Validation: Confirms that the model meets the business needs in a real-world scenario. This typically involves testing the model with data that was not used during the training phase.

The implementation of a structured validation lifecycle is aligned with the guidelines provided in standards such as GAMP 5, which outlines good practices for software validation. Ensuring comprehensive documentation throughout the V&V process is also critical for creating an audit trail that regulatory bodies require.

Step 5: Drift Monitoring & Re-validation

Once an AI/ML model is deployed, it is imperative to implement drift monitoring and re-validation procedures. Model drift refers to the degradation of model performance over time due to changes in input data, which can occur for various reasons, including the changed dynamics in the underlying data distribution. Key strategies include:

• Establishing Baseline Metrics: Set metrics that define acceptable model performance levels to detect drift effectively.
• Monitoring Performance Continuously: Use automated tools to track model performance and detect any anomalies that may indicate drift.
• Re-validation Protocols: When drift is detected, follow a re-validation protocol to assess the model’s updated performance and required adjustments.

These procedures not only enhance model reliability but also ensure adherence to ongoing compliance with relevant regulations and standards.

Step 6: Documentation and Audit Trails

Documenting each step of the model’s life cycle is critical. This includes all aspects from development through deployment to monitoring and maintenance. Proper documentation ensures clarity, provides transparency, and is essential for regulatory compliance. Key documentation practices include:

• Version Control: Maintain a history of all changes made to the model, including versions of software dependencies, dataset versions, and documentation.
• Audit Trails: Establish a system to track all actions taken on the AI models including who made changes and when.

Adhering to these practices ensures readiness for audits by regulatory bodies and facilitates continuous improvement in the development and application of AI/ML within GxP environments.

Step 7: AI Governance & Security

With the integration of AI/ML into pharmaceutical processes, establishing robust governance and security protocols is non-negotiable. AI governance involves defining policies, procedures, and assigned responsibilities associated with AI models. Key elements include:

• Compliance Frameworks: Develop compliance frameworks that align with both local and international regulations such as those outlined by EMA, FDA, and other relevant bodies.
• Security Protocols: Ensure that security measures are in place to protect data integrity and confidentiality. This can include access controls, encryption of data, and secure software development practices.

Ensuring adherence to governance and security measures diminishes risks associated with not just compliance, but also fosters trust in the AI/ML applications adopted.

Conclusion

The implementation of AI and ML in GxP environments requires navigating the complexities of model verification and validation while ensuring compliance with stringent regulatory requirements. By following this step-by-step tutorial, pharmaceutical professionals can enhance their understanding of how to ensure that AI/ML models are reproducible, secure, and reliable. Ongoing diligence in bias testing, drift monitoring, and governance will help ensure that these technologies meet the demands of the industry and regulatory expectations effectively.